Integra LifeSciences Holdings Corporation
IART
$17.42
$0.352.02%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 0.76% | 2.42% | -1.74% | 5.57% | -0.61% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.76% | 2.42% | -1.74% | 5.57% | -0.61% |
| Cost of Revenue | -0.71% | -2.39% | 10.21% | 5.79% | 11.36% |
| Gross Profit | 1.95% | 6.17% | -9.36% | 5.41% | -8.61% |
| SG&A Expenses | -2.24% | 3.51% | -2.89% | 1.21% | -2.65% |
| Depreciation & Amortization | 0.43% | 1.94% | 1.43% | -0.85% | 1.27% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.16% | -0.01% | 1.90% | 1.82% | 3.22% |
| Operating Income | 23.31% | 29.57% | -21.50% | 58.76% | -30.74% |
| Income Before Tax | 100.89% | 91.98% | -80.88% | 66.49% | -3,396.56% |
| Income Tax Expenses | 100.56% | 146.55% | 93.63% | 85.31% | -1,584.48% |
| Earnings from Continuing Operations | 100.93% | 81.75% | -108.77% | 49.47% | -3,803.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 100.93% | 81.75% | -108.77% | 49.47% | -3,803.18% |
| EBIT | 23.31% | 29.57% | -21.50% | 58.76% | -30.74% |
| EBITDA | 11.45% | 15.36% | -18.55% | 28.36% | -8.44% |
| EPS Basic | 100.92% | 81.86% | -108.73% | 49.68% | -3,839.89% |
| Normalized Basic EPS | 71.35% | 53.63% | -37.13% | 61.07% | -55.90% |
| EPS Diluted | 100.92% | 81.86% | -109.10% | 49.71% | -3,839.89% |
| Normalized Diluted EPS | 69.47% | 53.63% | -37.13% | 61.07% | -55.90% |
| Average Basic Shares Outstanding | 0.78% | 0.64% | 0.47% | 0.40% | -0.92% |
| Average Diluted Shares Outstanding | 1.92% | 0.64% | 0.47% | 0.40% | -0.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |